Amanda Gross, Ph.D.

Amanda Gross, Ph.D. is a Senior Scientist currently working at SeromYx Systems since September 2020. Prior to this, they worked as a Senior Scientist at GSK from November 2018 to August 2020, where they contributed to target validation for a regulatory T cell receptor agonist and investigated the mechanism of action of a lead immuno-oncology compound. From 2012 to 2018, Amanda worked as a Graduate Research Assistant in Pharmacology & Experimental Therapeutics at Tufts University School of Graduate Biomedical Sciences, focusing on the inhibitory potential and mechanism of action of glycosaminoglycans on mast cell activation. Amanda also gained experience as a Clinical Pharmacology Quantitative Sciences Summer Intern at Janssen, Pharmaceutical Companies of Johnson and Johnson in 2014, where they researched physiologically-based pharmacokinetic modeling. Additionally, Amanda was a University Scholars Program Fellow at the University of Florida, College of Pharmacy in 2011, conducting research on the correlation between haptoglobin genotypes and the risk of developing inflammatory bowel disease (IBD). Amanda also worked as a Research Assistant at the University of Miami, Miami Project to Cure Paralysis in 2010, quantifying Schwann cell survival and analyzing the gaits of spinal cord injured mice. Amanda's early research experience includes being an HHMI Group Advantaged Training of Research (GATOR) Program Fellow at the University of Florida, Department of Biology from 2009 to 2010, where they studied the fitness consequences of nest architecture preferences in convict cichlid fish.

Amanda Gross, Ph.D. completed their Bachelor of Science (B.S.) degree in Biology at the University of Florida, from 2008 to 2012. Following this, they pursued their Doctor of Philosophy (PhD) in Pharmacology & Experimental Therapeutics at Tufts University, from 2012 to 2018.